Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDVistagen Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.38 | -$0.30 | -$0.34 |
| Q2 2026 | 3 | -$0.30 | -$0.20 | -$0.25 |
| Q3 2026 | 1 | -$0.27 | -$0.27 | -$0.27 |
| Q4 2026 | 1 | -$0.28 | -$0.28 | -$0.28 |
| Q1 2027 | 1 | -$0.30 | -$0.30 | -$0.30 |
Vistagen Therapeutics Inc. Earnings Date And Information
Vistagen Therapeutics Inc. last posted its earnings results on Thursday, February 12th, 2026. The company reported $-0.45 earnings per share for the quarter, topping analysts' consensus estimates of $-0.51 by $0.06. The company had revenue of 303.00 K for the quarter and had revenue of 486.00 K for the year. Vistagen Therapeutics Inc. has generated $-2 earnings per share over the last year ($-1.67 diluted earnings per share) and currently has a price-to-earnings ratio of -0.38. Vistagen Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Vistagen Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/12/2026 | Q3 2026 | -$0.51 | -$0.45 | 0.06 | $364.43 K | $303.00 K |
| 11/13/2025 | Q2 2026 | -$0.51 | -$0.54 | -0.03 | $364.25 K | $258.00 K |
| 08/07/2025 | Q1 2026 | -$0.47 | -$0.47 | 0 | $647.00 K | $244.00 K |
| 06/17/2025 | Q4 2025 | -$0.52 | -$0.44 | 0.08 | $308.50 K | $-15,000 |
| 02/13/2025 | Q3 2025 | -$0.48 | -$0.46 | 0.02 | $224.67 K | $234.00 K |
| 11/07/2024 | Q2 2025 | -$0.40 | -$0.42 | -0.02 | $298.65 K | $183.00 K |
| 08/13/2024 | Q1 2025 | -$0.41 | -$0.35 | 0.06 | $405.70 K | $84.00 K |
| 06/11/2024 | Q4 2024 | -$0.34 | -$0.35 | -0.01 | $726.00 K | $197.30 K |
| 02/13/2024 | Q3 2024 | -$0.31 | -$0.43 | -0.12 | N/A | $411.40 K |
| 11/09/2023 | Q2 2024 | -$0.68 | -$0.66 | 0.02 | N/A | $278.00 K |
| 08/10/2023 | Q1 2024 | -$0.86 | -$0.94 | -0.08 | N/A | $177.00 K |
| 06/28/2023 | Q4 2023 | N/A | -$1.71 | N/A | N/A | $175.60 K |
| 02/07/2023 | Q3 2023 | -$1.80 | -$1.42 | 0.38 | N/A | $179.60 K |
| 11/10/2022 | Q2 2023 | -$2.40 | -$2.54 | -0.14 | N/A | $-892,500 |
| 08/11/2022 | Q1 2023 | -$2.70 | -$2.87 | -0.17 | N/A | $310.10 K |
| 06/23/2022 | Q4 2022 | -$1.80 | -$2.43 | -0.63 | N/A | $38.90 K |
| 02/10/2022 | Q3 2022 | -$2.40 | -$1.56 | 0.84 | N/A | $357.90 K |
| 11/10/2021 | Q2 2022 | -$1.50 | -$1.99 | -0.49 | N/A | $358.00 K |
| 08/12/2021 | Q1 2022 | -$1.50 | -$1.22 | 0.28 | N/A | $354.10 K |
| 06/29/2021 | Q4 2021 | -$1.50 | -$1.29 | 0.21 | N/A | $441.90 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Vistagen Therapeutics Inc. Earnings: FAQ's
In the previous quarter, Vistagen Therapeutics Inc. (:VTGN) reported $-0.45 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.51 by $0.06.
The conference call for Vistagen Therapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for Vistagen Therapeutics Inc.'s latest earnings report can be read online.
Vistagen Therapeutics Inc. (:VTGN) has a recorded annual revenue of $486.00 K.
Vistagen Therapeutics Inc. (:VTGN) has a recorded net income of $-51,418,000.Vistagen Therapeutics Inc. has generated $-1.67 earnings per share over the last four quarters.
Vistagen Therapeutics Inc. (:VTGN) has a price-to-earnings ratio of -0.38 and price/earnings-to-growth ratio is 0.02.